Fact CheckerSign in

NCT06170944Recruiting

Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke

Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke (RICAS): a Prospective, Randomized, Blind Endpoint, Multicenter Study

Source: ClinicalTrials.gov · Last updated 27 Apr 2026

Brief summary (registry, in English)

The goal of this clinical trial is to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
300 (estimated)
First submitted
5 Dec 2023
Start date
Jun 2024
Primary completion date
Nov 2026
Lead sponsor
General Hospital of Shenyang Military Region
Diseases
Stroke
NCT number
NCT06170944

What you commit to

  • Study type: Interventional
  • Planned participants: 300
  • From Jun 2024 to the primary completion date, Nov 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • 6\) Patients with intracranial hemorrhage (parenchymal hemorrhage, subarachnoid hemorrhage, subdural/epidural hemorrhage) within 90 days before enrollment;
  • 10\) Those who are expected to undergo major surgery (including femoral artery, cardiac, aortic or carotid artery surgery) within 30 days before enrollment or within 12 months after enrollment;
  • 11\) Those who have received stent implantation, angioplasty or other related medical devices for the target diseased blood vessels, or those who are expected to undergo the above treatments within 12 months after enrollment;

Other illness

  • 1\) Patients with severe infection or serious diseases such as liver, kidney, hematopoietic system, endocrine system, etc.;
  • 2\) Patients with a history of stroke and severe sequelae (mRS≥3);
  • 3\) arterial stenosis due to aortic dissection, moyamoya disease; Any known vasculitic disease; herpes zoster, varicella-zoster or other viral infections with vascular lesions; neurosyphilis; other intracranial infections; any intracranial artery stenosis associated with hypercytosis of cerebrospinal fluid; radiation-induced vascular lesions; myofiber dysplasia; sickle cell disease; neurofibromas; benign vascular lesions of the central nervous system; postpartum vascular disease; stenosis of the intracranial arteries due to vasospasm or thrombosm;
  • 4\) Uncontrolled severe hypertension (systolic pressure≥180mmHg or diastolic pressure≥110 mmHg after drug treatment) ;
  • 5\) Subclavian artery stenosis ≥50% or subclavian artery steal syndrome;
  • 8\) Patients with severe hematologic diseases or severe coagulation abnormalities;
  • 9\) Retinal hemorrhage or visceral hemorrhage within 30 days;

Other

  • 7\) Intracranial tumor, arteriovenous malformation, or aneurysm;
  • 12\) Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.
  • 13\) Damage and lesions in the cerebral veins;
  • 14\) Pregnant or lactating women;
  • 15\) Those who are participating in other clinical trials within 3 months;
  • 16\) Life expectancy is less than 1 year
  • 17\) Patients not suitable for this clinical studies considered by researcher

Who the study is looking for

  • 1\. Age over 40 years old;
  • 2\. Diagnosed with ischemic stroke (including TIA and cerebral infarction), with onset time of more than 1 month;
  • 3\. Culprit arteries are the large arteries of the anterior circulation with atherosclerotic stenosis (≥50%) or occlusion;
  • 4\. ASITN/SIR collateral circulation of 0-3 based on DSA evaluation;
  • 5\. First onset or prior onset with no significant sequelae (mRS ≤ 2);
  • 6\. Those who are not expected to undergo angioplasty within 12 months (judged by the doctor or decided by patients and/or their representatives);
  • 7\. The availability of informed consent.

Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
General Hospital of Northern Theater Command
Coordinator of this site? Confirm its status
ShenyangChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.